Oncology Drugs Market

Market Study on Oncology Drugs: North America Leads With Close to 50% Global Market Share

Oncology Drugs Market Segmented Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy Drug Class with Breast Cancer, Lung Cancer, Prostate Cancer, Multiple Myeloma, Colorectal Cancer, Non-Hodgkin's Lymphoma, Kidney Cancer, Melanoma indication with Oral and Injectable Route of Administration

  • September-2022
  • PMRREP3312
  • 406 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusion and Exclusion

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Inclusion

    4.1. Key Promotional Strategies, By Manufacturers

    4.2. Disease Epidemiology

    4.3. Pipeline Assessment

    4.4. Regulatory Landscape

    4.5. Reimbursement Outlook

    4.6. Product Adoption / Usage Analysis

    4.7. PESTLE Analysis

    4.8. Porter’s Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Industry Market Outlook

        5.1.3. Pharmaceutical Industry Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Rise In Incidence of Cancer

        5.2.2. Strong Product Pipeline

        5.2.3. Strategic Developments By Key Players

        5.2.4. Adoption Of Cell And Gene Therapies

        5.2.5. Growing Geriatric Population

        5.2.6. Regulatory Framework

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

    6.1. Impact of COVID-19 – 2021 Market Scenario

    6.2. COVID19 and Impact Analysis

7. Global Oncology Drugs Market Demand (in Value US$ Mn) Analysis 2012-2021 and Forecast, 2022-2032

    7.1. Historical Market Value (US$ Mn) Analysis, 2012-2021

    7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2020-2030, By Drug class

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Drug class, 2012-2021

    8.3. Current and Future Market Size (US$ Mn) Analysis By Drug class, 2022-2032

        8.3.1. Chemotherapy

            8.3.1.1. Alkylating agents.

            8.3.1.2. Antimetabolites.

            8.3.1.3. Anti-tumor antibiotics.

            8.3.1.4. Topoisomerase inhibitors.

            8.3.1.5. Mitotic inhibitors

            8.3.1.6. Others

        8.3.2. Targeted Therapy

            8.3.2.1. Monoclonal antibodies

            8.3.2.2. Small molecule inhibitors

        8.3.3. Immunotherapy

            8.3.3.1. Immune Checkpoint Inhibitors.

            8.3.3.2. Cell Therapy and Gene Therapy

            8.3.3.3. Oncolytic Virus Therapy.

            8.3.3.4. Cancer Vaccines.

            8.3.3.5. Immune System Modulators.

            8.3.3.6. Others

        8.3.4. Hormonal Therapy

    8.4. Market Attractiveness Analysis By Drug class

9. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2020-2030, By Indication

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Indication, 2012-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Indication, 2022-2032

        9.3.1. Breast Cancer

        9.3.2. Lung Cancer

        9.3.3. Prostate Cancer

        9.3.4. Multiple myeloma

        9.3.5. Colorectal Cancer

        9.3.6. Non-Hodgkin's lymphoma

        9.3.7. Kidney Cancer

        9.3.8. Chronic lymphocytic leukemia

        9.3.9. Melanoma

        9.3.10. Others

    9.4. Market Attractiveness Analysis by Indication

10. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2021

    10.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Route of Administration, 2022-2032

        10.3.1. Oral

        10.3.2. Injectable

    10.4. Market Attractiveness Analysis By Route of Administration

11. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2021

    11.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Distribution Channel, 2022-2032

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Others

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis by Region, 2012-2021

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2022-2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. South Asia

        12.3.5. East Asia

        12.3.6. Oceania

        12.3.7. Middle East & Africa(MEA)

    12.4. Market Attractiveness Analysis by Region

13. North America Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) by Market Taxonomy, 2012-2021

    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022 - 2032

        13.3.1. By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Drug class

        13.3.3. By Indication

        13.3.4. By Route of Administration

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug class

        13.4.3. By Indication

        13.4.4. By Route of Administration

        13.4.5. By Distribution Channel

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. U.S. Oncology Drugs Market

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Drug class

                13.8.1.2.2. By Indication

                13.8.1.2.3. By Route of Administration

                13.8.1.2.4. By Distribution Channel

        13.8.2. Canada Oncology Drugs Market

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Drug class

                13.8.2.2.2. By Indication

                13.8.2.2.3. By Route of Administration

                13.8.2.2.4. By Distribution Channel

14. Latin America Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2012-2021

    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022 - 2032

        14.3.1. By Country

            14.3.1.1. Brazil

            14.3.1.2. Mexico

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

        14.3.2. By Drug class

        14.3.3. By Indication

        14.3.4. By Route of Administration

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Drug class

        14.4.3. By Indication

        14.4.4. By Route of Administration

        14.4.5. By Distribution Channel

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Brazil Oncology Drugs Market

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Drug class

                14.8.1.2.2. By Indication

                14.8.1.2.3. By Route of Administration

                14.8.1.2.4. By Distribution Channel

        14.8.2. Mexico Oncology Drugs Market

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Drug class

                14.8.2.2.2. By Indication

                14.8.2.2.3. By Route of Administration

                14.8.2.2.4. By Distribution Channel

        14.8.3. Argentina Oncology Drugs Market

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Drug class

                14.8.3.2.2. By Indication

                14.8.3.2.3. By Route of Administration

                14.8.3.2.4. By Distribution Channel

15. Europe Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021

    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 - 2032

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. BENELUX

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Drug class

        15.3.3. By Indication

        15.3.4. By Route of Administration

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug class

        15.4.3. By Indication

        15.4.4. By Route of Administration

        15.4.5. By Distribution Channel

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. Germany Oncology Drugs Market

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Drug class

                15.8.1.2.2. By Indication

                15.8.1.2.3. By Route of Administration

                15.8.1.2.4. By Distribution Channel

        15.8.2. Italy Oncology Drugs Market

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Drug class

                15.8.2.2.2. By Indication

                15.8.2.2.3. By Route of Administration

                15.8.2.2.4. By Distribution Channel

        15.8.3. France Oncology Drugs Market

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Drug class

                15.8.3.2.2. By Indication

                15.8.3.2.3. By Route of Administration

                15.8.3.2.4. By Distribution Channel

        15.8.4. U.K. Oncology Drugs Market

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Drug class

                15.8.4.2.2. By Indication

                15.8.4.2.3. By Route of Administration

                15.8.4.2.4. By Distribution Channel

        15.8.5. Spain Oncology Drugs Market

            15.8.5.1. Introduction

            15.8.5.2. Market Analysis and Forecast by Market Taxonomy

                15.8.5.2.1. By Drug class

                15.8.5.2.2. By Indication

                15.8.5.2.3. By Route of Administration

                15.8.5.2.4. By Distribution Channel

        15.8.6. BENELUX Oncology Drugs Market

            15.8.6.1. Introduction

            15.8.6.2. Market Analysis and Forecast by Market Taxonomy

                15.8.6.2.1. By Drug class

                15.8.6.2.2. By Indication

                15.8.6.2.3. By Route of Administration

                15.8.6.2.4. By Distribution Channel

        15.8.7. Russia Oncology Drugs Market

            15.8.7.1. Introduction

            15.8.7.2. Market Analysis and Forecast by Market Taxonomy

                15.8.7.2.1. By Drug class

                15.8.7.2.2. By Indication

                15.8.7.2.3. By Route of Administration

                15.8.7.2.4. By Distribution Channel

16. South Asia Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021

    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 - 2032

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. Thailand

            16.3.1.3. Indonesia

            16.3.1.4. Malaysia

            16.3.1.5. Rest of South Asia

        16.3.2. By Drug class

        16.3.3. By Indication

        16.3.4. By Route of Administration

        16.3.5. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug class

        16.4.3. By Indication

        16.4.4. By Route of Administration

        16.4.5. By Distribution Channel

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. India Oncology Drugs Market

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Drug class

                16.8.1.2.2. By Indication

                16.8.1.2.3. By Route of Administration

                16.8.1.2.4. By Distribution Channel

        16.8.2. Thailand Oncology Drugs Market

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Drug class

                16.8.2.2.2. By Indication

                16.8.2.2.3. By Route of Administration

                16.8.2.2.4. By Distribution Channel

        16.8.3. Indonesia Oncology Drugs Market

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Drug class

                16.8.3.2.2. By Indication

                16.8.3.2.3. By Route of Administration

                16.8.3.2.4. By Distribution Channel

        16.8.4. Malaysia Oncology Drugs Market

            16.8.4.1. Introduction

            16.8.4.2. Market Analysis and Forecast by Market Taxonomy

                16.8.4.2.1. By Drug class

                16.8.4.2.2. By Indication

                16.8.4.2.3. By Route of Administration

                16.8.4.2.4. By Distribution Channel

17. East Asia Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021

    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 - 2032

        17.3.1. By Country

            17.3.1.1. China

            17.3.1.2. Japan

            17.3.1.3. South Korea

        17.3.2. By Drug class

        17.3.3. By Indication

        17.3.4. By Route of Administration

        17.3.5. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug class

        17.4.3. By Indication

        17.4.4. By Route of Administration

        17.4.5. By Distribution Channel

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. China Oncology Drugs Market

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Drug class

                17.8.1.2.2. By Indication

                17.8.1.2.3. By Route of Administration

                17.8.1.2.4. By Distribution Channel

        17.8.2. Japan Oncology Drugs Market

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Drug class

                17.8.2.2.2. By Indication

                17.8.2.2.3. By Route of Administration

                17.8.2.2.4. By Distribution Channel

        17.8.3. South Korea Oncology Drugs Market

            17.8.3.1. Introduction

            17.8.3.2. Market Analysis and Forecast by Market Taxonomy

                17.8.3.2.1. By Drug class

                17.8.3.2.2. By Indication

                17.8.3.2.3. By Route of Administration

                17.8.3.2.4. By Distribution Channel

18. Oceania Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021

    18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 - 2032

        18.3.1. By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. B By Drug class

        18.3.3. By Indication

        18.3.4. By Route of Administration

        18.3.5. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug class

        18.4.3. By Indication

        18.4.4. By Route of Administration

        18.4.5. By Distribution Channel

    18.5. Country Level Analysis & Forecast

        18.5.1. Australia Oncology Drugs Market

            18.5.1.1. Introduction

            18.5.1.2. Market Analysis and Forecast by Market Taxonomy

                18.5.1.2.1. By Drug class

                18.5.1.2.2. By Indication

                18.5.1.2.3. By Route of Administration

                18.5.1.2.4. By Distribution Channel

        18.5.2. New Zealand Oncology Drugs Market

            18.5.2.1. Introduction

            18.5.2.2. Market Analysis and Forecast by Market Taxonomy

                18.5.2.2.1. By Drug class

                18.5.2.2.2. By Indication

                18.5.2.2.3. By Route of Administration

                18.5.2.2.4. By Distribution Channel

19. MEA Oncology Drugs Market Analysis 2012-2021and Forecast 2022-2032

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021

    19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 - 2032

        19.3.1. By Country

            19.3.1.1. GCC Countries

            19.3.1.2. Turkey

            19.3.1.3. South Africa

            19.3.1.4. North Africa

            19.3.1.5. Rest of MEA

        19.3.2. By Drug class

        19.3.3. By Indication

        19.3.4. By Route of Administration

        19.3.5. By Distribution Channel

    19.4. Market Attractiveness Analysis

        19.4.1. By Country

        19.4.2. By Drug class

        19.4.3. By Indication

        19.4.4. By Route of Administration

        19.4.5. By Distribution Channel

    19.5. Market Trends

    19.6. Key Market Participants - Intensity Mapping

    19.7. Drivers and Restraints - Impact Analysis

    19.8. Country Level Analysis & Forecast

        19.8.1. GCC Countries Oncology Drugs Market

            19.8.1.1. Introduction

            19.8.1.2. Market Analysis and Forecast by Market Taxonomy

                19.8.1.2.1. By Drug class

                19.8.1.2.2. By Indication

                19.8.1.2.3. By Route of Administration

                19.8.1.2.4. By Distribution Channel

        19.8.2. Turkey Oncology Drugs Market

            19.8.2.1. Introduction

            19.8.2.2. Market Analysis and Forecast by Market Taxonomy

                19.8.2.2.1. By Drug class

                19.8.2.2.2. By Indication

                19.8.2.2.3. By Route of Administration

                19.8.2.2.4. By Distribution Channel

        19.8.3. South Africa Oncology Drugs Market

            19.8.3.1. Introduction

            19.8.3.2. Market Analysis and Forecast by Market Taxonomy

                19.8.3.2.1. By Drug class

                19.8.3.2.2. By Indication

                19.8.3.2.3. By Route of Administration

                19.8.3.2.4. By Distribution Channel

        19.8.4. North Africa Oncology Drugs Market

            19.8.4.1. Introduction

            19.8.4.2. Market Analysis and Forecast by Market Taxonomy

                19.8.4.2.1. By Drug class

                19.8.4.2.2. By Indication

                19.8.4.2.3. By Route of Administration

                19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies

    20.2. Market Share Analysis of Top Players

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive (Tentative List)

        21.3.1. GlaxoSmithKline plc.

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. SWOT Analysis

            21.3.1.4. Strategy Overview

                21.3.1.4.1. Marketing Strategies

                21.3.1.4.2. Product Strategies

                21.3.1.4.3. Channel Strategies

        21.3.2. Astrazeneca

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. SWOT Analysis

            21.3.2.4. Strategy Overview

                21.3.2.4.1. Marketing Strategies

                21.3.2.4.2. Product Strategies

                21.3.2.4.3. Channel Strategies

        21.3.3. Merck KGaA

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. SWOT Analysis

            21.3.3.4. Strategy Overview

                21.3.3.4.1. Marketing Strategies

                21.3.3.4.2. Product Strategies

                21.3.3.4.3. Channel Strategies

        21.3.4. Johnson & Johnson

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. SWOT Analysis

            21.3.4.4. Strategy Overview

                21.3.4.4.1. Marketing Strategies

                21.3.4.4.2. Product Strategies

                21.3.4.4.3. Channel Strategies

        21.3.5. Pfizer, Inc.

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. SWOT Analysis

            21.3.5.4. Strategy Overview

                21.3.5.4.1. Marketing Strategies

                21.3.5.4.2. Product Strategies

                21.3.5.4.3. Channel Strategies

        21.3.6. Bayer AG

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. SWOT Analysis

            21.3.6.4. Strategy Overview

                21.3.6.4.1. Marketing Strategies

                21.3.6.4.2. Product Strategies

                21.3.6.4.3. Channel Strategies

        21.3.7. Sanofi S.A.

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. SWOT Analysis

            21.3.7.4. Strategy Overview

                21.3.7.4.1. Marketing Strategies

                21.3.7.4.2. Product Strategies

                21.3.7.4.3. Channel Strategies

        21.3.8. Boehringer Ingelheim

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. SWOT Analysis

            21.3.8.4. Strategy Overview

                21.3.8.4.1. Marketing Strategies

                21.3.8.4.2. Product Strategies

                21.3.8.4.3. Channel Strategies

        21.3.9. Bausch Health Companies Inc.

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. SWOT Analysis

            21.3.9.4. Strategy Overview

                21.3.9.4.1. Marketing Strategies

                21.3.9.4.2. Product Strategies

                21.3.9.4.3. Channel Strategies

        21.3.10. Galderma SA

            21.3.10.1. Overview

            21.3.10.2. Product Portfolio

            21.3.10.3. SWOT Analysis

            21.3.10.4. Strategy Overview

                21.3.10.4.1. Marketing Strategies

                21.3.10.4.2. Product Strategies

                21.3.10.4.3. Channel Strategies

        21.3.11. Novartis AG (Alcon)

            21.3.11.1. Overview

            21.3.11.2. Product Portfolio

            21.3.11.3. SWOT Analysis

            21.3.11.4. Strategy Overview

                21.3.11.4.1. Marketing Strategies

                21.3.11.4.2. Product Strategies

                21.3.11.4.3. Channel Strategies

        21.3.12. Arbor Pharmaceuticals

            21.3.12.1. Overview

            21.3.12.2. Product Portfolio

            21.3.12.3. SWOT Analysis

            21.3.12.4. Strategy Overview

                21.3.12.4.1. Marketing Strategies

                21.3.12.4.2. Product Strategies

                21.3.12.4.3. Channel Strategies

        21.3.13. Perrigo Company Plc.

            21.3.13.1. Overview

            21.3.13.2. Product Portfolio

            21.3.13.3. SWOT Analysis

            21.3.13.4. Strategy Overview

                21.3.13.4.1. Marketing Strategies

                21.3.13.4.2. Product Strategies

                21.3.13.4.3. Channel Strategies

        21.3.14. Allergan

            21.3.14.1. Overview

            21.3.14.2. Product Portfolio

            21.3.14.3. SWOT Analysis

            21.3.14.4. Strategy Overview

                21.3.14.4.1. Marketing Strategies

                21.3.14.4.2. Product Strategies

                21.3.14.4.3. Channel Strategies

        21.3.15. Lupin

            21.3.15.1. Overview

            21.3.15.2. Product Portfolio

            21.3.15.3. SWOT Analysis

            21.3.15.4. Strategy Overview

                21.3.15.4.1. Marketing Strategies

                21.3.15.4.2. Product Strategies

                21.3.15.4.3. Channel Strategies

        21.3.16. Teva pharmaceuticals

            21.3.16.1. Overview

            21.3.16.2. Product Portfolio

            21.3.16.3. SWOT Analysis

            21.3.16.4. Strategy Overview

                21.3.16.4.1. Marketing Strategies

                21.3.16.4.2. Product Strategies

                21.3.16.4.3. Channel Strategies

        21.3.17. Ultragenyx Pharmaceutical Inc

            21.3.17.1. Overview

            21.3.17.2. Product Portfolio

            21.3.17.3. SWOT Analysis

            21.3.17.4. Strategy Overview

                21.3.17.4.1. Marketing Strategies

                21.3.17.4.2. Product Strategies

                21.3.17.4.3. Channel Strategies

        21.3.18. Zydus Cadila Healthcare Ltd.

            21.3.18.1. Overview

            21.3.18.2. Product Portfolio

            21.3.18.3. SWOT Analysis

            21.3.18.4. Strategy Overview

                21.3.18.4.1. Marketing Strategies

                21.3.18.4.2. Product Strategies

                21.3.18.4.3. Channel Strategies

        21.3.19. Glenmark Pharmaceuticals

            21.3.19.1. Overview

            21.3.19.2. Product Portfolio

            21.3.19.3. SWOT Analysis

            21.3.19.4. Strategy Overview

                21.3.19.4.1. Marketing Strategies

                21.3.19.4.2. Product Strategies

                21.3.19.4.3. Channel Strategies

22. Assumptions and Acronyms Used

23. Research Methodology

Find Out More about the Report Coverage

List of Tables

Table 01 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 01 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 01 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 01 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 02 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 02 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 03 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 03 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 04 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 04 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 05 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Region

Table 05 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Region

Table 06 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 06 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 07 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 07 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 07 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 07 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 08 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 08 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 09 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 09 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 10 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 10 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 11 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 11 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 12 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 12 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 12 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 12 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 13 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 13 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 14 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 14 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 15 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 15 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 16 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 16 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 17 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 17 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 17 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 17 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 18 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 18 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 19 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 19 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 20 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 20 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 21 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 21 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 22 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 22 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 22 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 22 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 23 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 23 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 24 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 24 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 25 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 25 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 26 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 26 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 27 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 27 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 27 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 27 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 28 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 28 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 29 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 29 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 30 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 30 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 31 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 31 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 32 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 32 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 32 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 32 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 33 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 33 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 34 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 34 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 35 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 35 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 36 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 36 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country

Table 37 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 37 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 37 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 37 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class

Table 38 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 38 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication

Table 39 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 39 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration

Table 40 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Table 40 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel

Explore Persistence Market Research’s expertise in promulgation of the business !

List of Chart

Figure 01: Global Oncology Drugs Market Value Share By Drug Class (2022 E)

Figure 02: Global Oncology Drugs Market Value Share By Indication (2022 E)

Figure 03: Global Oncology Drugs Market Value Share By Route of administration (2022 E)

Figure 04: Global Oncology Drugs Market Value Share By Distribution Channel (2022 E)

Figure 05: Global Oncology Drugs Market Value Share By Region (2022 E)

Figure 06: Global Oncology Drugs Market Size (US$ Bn) Analysis, 2012-2021

Figure 07: Global Oncology Drugs Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 08: Global Oncology Drugs Market Absolute $ Opportunity Analysis, 2022-2032

Figure 09: Global Oncology Drugs Market Analysis by Drug Class –2021 & 2032

Figure 10: Global Oncology Drugs Market Attractiveness, by Drug Class, 2022- 2032

Figure 11: Global Oncology Drugs Market Analysis by Indication –2021 & 2032

Figure 12: Global Oncology Drugs Market Attractiveness, By Indication, 2022- 2032

Figure 13: Global Oncology Drugs Market Analysis By Route of Administration –2021 & 2032

Figure 14: Global Oncology Drugs Market Attractiveness, By Route of Administration, 2022- 2032

Figure 15: Global Oncology Drugs Market Analysis By Distribution Channel –2021 & 2032

Figure 16: Global Oncology Drugs Market Attractiveness, By Distribution Channel, 2022- 2032

Figure 17: Global Oncology Drugs Market Analysis by Region–2021 & 2032

Figure 18: Global Oncology Drugs Market Attractiveness, By Region, 2022-2032

Figure 19: North America Oncology Drugs Market Value Share, by Drug Class 2022 (E)

Figure 20: North America Oncology Drugs Market Value Share, By Indication 2022 (E)

Figure 21: North America Oncology Drugs Market Value Share, By Route of Administration 2022 (E)

Figure 22: North America Oncology Drugs Market Value Share, By Distribution Channel 2022 (E)

Figure 23: North America Oncology Drugs Market Value Share, by Country 2022 (E)

Figure 24: North America Oncology Drugs Market Size (US$ Bn) Analysis, 2012-2021

Figure 25: North America Oncology Drugs Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 26: North America Oncology Drugs Market Attractiveness Analysis , by Country

Figure 27: North America Oncology Drugs Market Attractiveness Analysis, by Drug Class

Figure 28: North America Oncology Drugs Market Attractiveness, By Indication

Figure 29: North America Oncology Drugs Market Attractiveness, By Route of Administration

Figure 30: North America Oncology Drugs Market Attractiveness, By Distribution Channel

Figure 31: U.S. Market Value Proportion Analysis, 2021

Figure 32: U.S. Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 33: U.S. Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 34: U.S. Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 35: U.S. Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 36: Canada Market Value Proportion Analysis, 2021

Figure 37: Canada Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 38: Canada Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 39: Canada Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 40: Canada Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 41: Latin America Oncology Drugs Market Value Share, by Drug Class 2022 (E)

Figure 42: Latin America Oncology Drugs Market Value Share, By Indication 2022 (E)

Figure 43: Latin America Oncology Drugs Market Value Share, By Route of Administration 2022 (E)

Figure 44: Latin America Oncology Drugs Market Value Share, By Distribution Channel 2022 (E)

Figure 45: Latin America Oncology Drugs Market Value Share, by Country 2022 (E)

Figure 46: Latin America Oncology Drugs Market Size (US$ Bn) Analysis, 2012-2021

Figure 47: Latin America Oncology Drugs Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 48: Latin America Oncology Drugs Market Attractiveness Analysis , by Country

Figure 49: Latin America Oncology Drugs Market Attractiveness Analysis, by Drug Class

Figure 50: Latin America Oncology Drugs Market Attractiveness, By Indication

Figure 51: Latin America Oncology Drugs Market Attractiveness, By Route of Administration

Figure 52: Latin America Oncology Drugs Market Attractiveness, By Distribution Channel

Figure 53: Brazil Market Value Proportion Analysis, 2021

Figure 54: Brazil Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 55: Brazil Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 56: Brazil Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 57: Brazil Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 58: Mexico Market Value Proportion Analysis, 2021

Figure 59: Mexico Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 60: Mexico Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 61: Mexico Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 62: Mexico Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 63: Argentina Market Value Proportion Analysis, 2021

Figure 64: Argentina Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 65: Argentina Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 66: Argentina Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 67: Argentina Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 68: Europe Oncology Drugs Market Value Share, by Drug Class 2022 (E)

Figure 69: Europe Oncology Drugs Market Value Share, By Indication 2022 (E)

Figure 70: Europe Oncology Drugs Market Value Share, By Route of Administration 2022 (E)

Figure 71: Europe Oncology Drugs Market Value Share, By Distribution Channel 2022 (E)

Figure 72: Europe Oncology Drugs Market Value Share, by Region 2022 (E)

Figure 73: Europe Oncology Drugs Market Size (US$ Bn) Analysis, 2012-2021

Figure 74: Europe Oncology Drugs Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 75: Europe Oncology Drugs Market Attractiveness Analysis , by Country

Figure 76: Europe Oncology Drugs Market Attractiveness Analysis, by Drug Class

Figure 77: Europe Oncology Drugs Market Attractiveness, By Indication

Figure 78: Europe Oncology Drugs Market Attractiveness, By Route of Administration

Figure 79: Europe Oncology Drugs Market Attractiveness, By Distribution Channel

Figure 80: U.K. Market Value Proportion Analysis, 2021

Figure 81: U.K. Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 82: U.K. Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 83: U.K. Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 84: U.K. Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 85: Germany Market Value Proportion Analysis, 2021

Figure 86: Germany Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 87: Germany Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 88: Germany Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 89: Germany Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 90: Italy Market Value Proportion Analysis, 2021

Figure 91: Italy Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 92: Italy Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 93: Italy Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 94: Italy Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 95: France Market Value Proportion Analysis, 2021

Figure 96: France Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 97: France Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 98: France Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 99: France Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 100: Spain Market Value Proportion Analysis, 2021

Figure 101: Spain Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 102: Spain Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 103: Spain Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 104: Spain Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 105: Russia Market Value Proportion Analysis, 2021

Figure 106: Russia Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 107: Russia Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 108: Russia Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 109: Russia Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 110: BENELUX Market Value Proportion Analysis, 2021

Figure 111: BENELUX Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 112: BENELUX Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 113: Spain Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 114: BENELUX Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 115: South Asia Oncology Drugs Market Value Share, by Drug Class 2022 (E)

Figure 116: South Asia Oncology Drugs Market Value Share, By Indication 2022 (E)

Figure 117: South Asia Oncology Drugs Market Value Share, By Route of Administration 2022 (E)

Figure 118: South Asia Oncology Drugs Market Value Share, By Distribution Channel 2022 (E)

Figure 119: South Asia Oncology Drugs Market Value Share, by Region 2022 (E)

Figure 120: South Asia Oncology Drugs Market Size (US$ Bn) Analysis, 2012-2021

Figure 121: South Asia Oncology Drugs Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 122: South Asia Oncology Drugs Market Attractiveness Analysis , by Country

Figure 123: South Asia Oncology Drugs Market Attractiveness Analysis, by Drug Class

Figure 124: South Asia Oncology Drugs Market Attractiveness, By Indication

Figure 125: South Asia Oncology Drugs Market Attractiveness, By Route of Administration

Figure 126: South Asia Oncology Drugs Market Attractiveness, By Distribution Channel

Figure 127: India Market Value Proportion Analysis, 2021

Figure 128: India Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 129: India Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 130: India Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 131: India Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 132: Thailand Market Value Proportion Analysis, 2021

Figure 133: Thailand Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 134: Thailand Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 135: Thailand Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 136: Thailand Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 137: Malaysia Market Value Proportion Analysis, 2021

Figure 138: Malaysia Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 139: Malaysia Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 140: Malaysia Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 141: Malaysia Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 142: France Market Value Proportion Analysis, 2021

Figure 143: France Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 144: France Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 145: France Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 146: France Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 147: East Asia Oncology Drugs Market Value Share, by Drug Class 2022 (E)

Figure 148: East Asia Oncology Drugs Market Value Share, By Indication 2022 (E)

Figure 149: East Asia Oncology Drugs Market Value Share, By Route of Administration 2022 (E)

Figure 150: East Asia Oncology Drugs Market Value Share, By Distribution Channel 2022 (E)

Figure 151: East Asia Oncology Drugs Market Value Share, by Region 2022 (E)

Figure 152: East Asia Oncology Drugs Market Size (US$ Bn) Analysis, 2012-2021

Figure 153: East Asia Oncology Drugs Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 154: East Asia Oncology Drugs Market Attractiveness Analysis , by Country

Figure 155: East Asia Oncology Drugs Market Attractiveness Analysis, by Drug Class

Figure 156: East Asia Oncology Drugs Market Attractiveness, By Indication

Figure 157: East Asia Oncology Drugs Market Attractiveness, By Route of Administration

Figure 158: East Asia Oncology Drugs Market Attractiveness, By Distribution Channel

Figure 159: China Market Value Proportion Analysis, 2021

Figure 160: China Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 161: China Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 162: China Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 163: China Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 164: Japan Market Value Proportion Analysis, 2021

Figure 165: Japan Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 166: Japan Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 167: Japan Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 168: Japan Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 169: South Korea Market Value Proportion Analysis, 2021

Figure 170: South Korea Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 171: South Korea Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 172: South Korea Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 173: South Korea Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 174: Oceania Oncology Drugs Market Value Share, by Drug Class 2022 (E)

Figure 175: Oceania Oncology Drugs Market Value Share, By Indication 2022 (E)

Figure 176: Oceania Oncology Drugs Market Value Share, By Route of Administration 2022 (E)

Figure 177: Oceania Oncology Drugs Market Value Share, By Distribution Channel 2022 (E)

Figure 178: Oceania Oncology Drugs Market Value Share, by Region 2022 (E)

Figure 179: Oceania Oncology Drugs Market Size (US$ Bn) Analysis, 2012-2021

Figure 180: Oceania Oncology Drugs Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 181: Oceania Oncology Drugs Market Attractiveness Analysis , by Country

Figure 182: Oceania Oncology Drugs Market Attractiveness Analysis, by Drug Class

Figure 183: Oceania Oncology Drugs Market Attractiveness, By Indication

Figure 184: Oceania Oncology Drugs Market Attractiveness, By Route of Administration

Figure 185: Oceania Oncology Drugs Market Attractiveness, By Distribution Channel

Figure 186: Australia Market Value Proportion Analysis, 2021

Figure 187: Australia Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 188: Australia Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 189: Australia Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 190: Australia Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 191: New Zealand Market Value Proportion Analysis, 2021

Figure 192: New Zealand Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 193: New Zealand Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 194: New Zealand Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 195: New Zealand Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 196: MEA Oncology Drugs Market Value Share, by Drug Class 2022 (E)

Figure 197: MEA Oncology Drugs Market Value Share, By Indication 2022 (E)

Figure 198: MEA Oncology Drugs Market Value Share, By Route of Administration 2022 (E)

Figure 199: MEA Oncology Drugs Market Value Share, By Distribution Channel 2022 (E)

Figure 200: MEA Oncology Drugs Market Value Share, by Region 2022 (E)

Figure 201: MEA Oncology Drugs Market Size (US$ Bn) Analysis, 2012-2021

Figure 202: MEA Oncology Drugs Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022-2032

Figure 203: MEA Oncology Drugs Market Attractiveness Analysis , by Country

Figure 204: MEA Oncology Drugs Market Attractiveness Analysis, by Drug Class

Figure 205: MEA Oncology Drugs Market Attractiveness, By Indication

Figure 206: MEA Oncology Drugs Market Attractiveness, By Route of Administration

Figure 207: MEA Oncology Drugs Market Attractiveness, By Distribution Channel

Figure 208: Turkey Market Value Proportion Analysis, 2021

Figure 209: Turkey Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 210: Turkey Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 211: Turkey Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 212: Turkey Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 213: GCC Countries Market Value Proportion Analysis, 2021

Figure 214: GCC Countries Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 215: GCC Countries Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 216: GCC Countries Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 217: GCC Countries Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 218: South Africa Market Value Proportion Analysis, 2021

Figure 219: South Africa Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 220: GCC Countries Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 221: GCC Countries Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 222: GCC Countries Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Figure 223: North Africa Market Value Proportion Analysis, 2021

Figure 224: North Africa Oncology Drugs Market Share Analysis (%), By Drug Class, 2021 & 2032

Figure 225: North Africa Oncology Drugs Market Share Analysis (%), By Indication, 2021 & 2032

Figure 226: North Africa Oncology Drugs Market Share Analysis (%), By Route of Administration, 2021 & 2032

Figure 227: North Africa Oncology Drugs Market Share Analysis (%), By Distribution Channel, 2021 & 2032

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Description

Oncology Drugs Market: Scope of Report

The latest publication by Persistence Market Research on the global oncology drugs market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for the global oncology drugs market and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the global oncology drugs market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the global oncology drugs market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the global oncology drugs market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the global oncology drugs market offers information divided into five important segments – drug class, indication, route of administration, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug Class

  • Chemotherapy
    • Alkylating Agents
    • Antimetabolites
    • Anti-tumour Antibiotics
    • Topoisomerase Inhibitors
    • Mitotic Inhibitors
    • Others
  • Targeted Therapy
    • Monoclonal Antibodies
    • Small Molecule Inhibitors
  • Immunotherapy
    • Immune Checkpoint Inhibitors
    • Cell Therapy and Gene Therapy
    • Oncolytic Virus Therapy
    • Cancer Vaccines
    • Immune System Modulators
    • Others
  • Hormonal Therapy

Indication

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Multiple Myeloma
  • Colorectal Cancer
  • Non-Hodgkin's Lymphoma
  • Kidney Cancer
  • Chronic lymphocytic Leukemia
  • Melanoma
  • Others

Route of Administration

  • Oral
  • Injectable

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Key Questions Answered in Report

  • Which regions will continue to remain the most profitable markets for oncology drugs over the coming years?
  • How will changing trends impact the market?
  • How has the COVID-19 crisis impacted market growth?
  • How can market players capture the low-hanging opportunities in developed regions?
  • What are the strategies of stakeholders in the market to shape their position in this landscape?
  • What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
  • What are the developmental trends that will impact the market?
  • How can companies in the oncology drugs market avail themselves of the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the oncology drugs market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the oncology drugs market more accurate and reliable.

Recommendations

Polyol Ester Market

As per PMR's research study, global polyol ester market anticipated to rise at a robust CAGR of 5.1% along with a healthy revenue during the forecast period of 2017-2027.

Propylene Glycol Ether Market

The global propylene glycol ether market is estimated to have been valued at US$ 1,604.1 Mn by 2017 end and is expected to reach US$ 2,088.4 Mn by the end of 2026 while expanding at a CAGR of 3.0% over the forecast period. .

Behenyl Alcohol Market

The behenyl alcohol market has seen steady demand from the cosmetics industry. Moreover, globally, per capita consumption of cosmetics is increasing at a rate of 3.4% per year.

Methyl Ethyl Ketone Market

The expected value of the global MEK market is expected to be US$ 800.2 Mn in 2018 and the market is estimated to reach US$ 1,055.6 Mn by the end of forecast period..

Our Clients

Our Clients